Yazen Health, a digital healthcare provider based in Lund, Sweden, has secured €50 million in funding through an investment partnership led by European growth investor Verdane. This round also saw participation from existing investor Evli Growth Partners. The investment will bolster Yazen's capacity to treat obesity, positioning it as a chronic disease requiring ongoing management through its innovative model.
Yazen specializes in integrating weight-loss medications with continuous digital support from a multidisciplinary healthcare team, including doctors and dietitians. According to Yazen, over 50,000 patients are currently receiving treatment via its platform. The new funds will help Yazen expand its offerings across Europe, enhancing its cardiometabolic care capabilities in countries such as Norway, Denmark, and Germany.
With this capital injection, Yazen is well-positioned to scale its evidence-based obesity care model further, addressing a rising demand for sustained support in managing obesity.